YTHDF1 and breast cancer: For example, YTHDF1 overexpression is a not desirable signature for BC patients and is linked to lower immune infiltrate and poor clinical outcomes, while YTHDF1 inhibition promotes the proliferation, migration, and invasion in BC cell lines (Li et al., 2022).